Medical researchers are using what they know about our immune system and computers to make startling advances. There has never been a better time for investors.
Shares of Moderna (MRNA) closed Tuesday up 19.6% after company executives announced a jointly developed vaccine showed great efficacy fighting cancer in stage 3 and 4 melanoma patients.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased